Kim Duncan Senior Director, Investor Relations ir@cooperco.com 6140 Stoneridge Mall Road Suite 590 Pleasanton, CA 94588 925-460-3663 www.coopercos.com

THE COOPER COMPANIES COMPLETES DIVESTITURE OF AIME

PLEASANTON, Calif., November 7, 2013 The Cooper Companies, Inc. (NYSE: COO) today announced that it has completed the sale of Aime, its

rigid gas permeable contact lens and solutions business in Japan, to Nippon Contact Lens Inc. effective October 31, 2013. The Company will recognize a fiscal fourth quarter 2013 charge to GAAP earnings per share of $0.25-$0.30. This charge will

be excluded from fiscal fourth quarter 2013 non-GAAP earnings per share. Aime revenues for fiscal 2013 were $25.3 million, and post divestiture the Company expects the transaction to be neutral to earnings per share.

About The Cooper Companies

The Cooper Companies, Inc.

( Cooper ) is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company with a focus on delivering shareholder value. Cooper operates through two business

units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support.

CooperSurgical focuses on supplying women s health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 8,000 employees with products sold

in over 100 countries. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Statements relating

to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2013 Guidance and all statements regarding anticipated growth in our

revenue, expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like believes, expects, may, will, should,

could, seeks, intends, plans, estimates or anticipates and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may

be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ

materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing

uncertainty and instability of certain European Union countries that could adversely affect our global markets; foreign currency exchange rate and interest rate fluctuations including the risk of further

declines in the value of the yen and the euro that would decrease our revenues and earnings; acquisition

integration delays or costs or the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period; a major disruption in the operations of our manufacturing,

research and development or distribution facilities due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; legal costs,

insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent or other litigation; limitations on sales following new product introductions due to poor market acceptance; new competitors,

product innovations or technologies; the impact of acquisitions or divestitures on revenues, earnings or margins; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including

goodwill; changes in United States and foreign government regulations of the retail optical industry and of the healthcare industry generally; changes in tax laws or their interpretation and changes in effective tax rates; dilution to earnings per

share from acquisitions or issuing stock and other events described in our Securities and Exchange Commission filings, including the Business and Risk Factors sections in the Company s Annual Report on Form 10-K for the

fiscal year ended October 31, 2012, as such Risk Factors may be updated in quarterly filings.

We caution investors that forward-looking statements

reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.